IDH1 and acute myeloid leukemia: In a reported clinical study of 146 patients with IDH1 mutated AML, the combination group of ivosidenib and azacitidine significantly prolonged the median overall survival and reduced the incidence of common adverse events.,76 which is generally consistent with the findings of the AML-295 AGILE phase 3 clinical trial.77